/FOLD
FOLD Stock - Amicus Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$14.18+30.21%
+$3.29 (+30.21%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.99
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).55
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+2.3%upside
Target: $14.51
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for FOLD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$14.04 – $14.32
TARGET (TP)$14.50
STOP LOSS$13.05
RISK/REWARD1:0.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.46
52W High$14.36
52W Low$5.51
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $528.29M | $399.36M | $329.23M | $305.51M | $260.89M |
| Gross Profit | $475.35M | $362.03M | $290.63M | $271.05M | $229.84M |
| Gross Margin | 90.0% | 90.7% | 88.3% | 88.7% | 88.1% |
| Operating Income | $24.88M | $-77,211,000 | $-212,120,000 | $-206,434,000 | $-246,998,000 |
| Net Income | $-56,106,000 | $-151,584,000 | $-236,568,000 | $-250,460,000 | $-276,852,000 |
| Net Margin | -10.6% | -38.0% | -71.9% | -82.0% | -106.1% |
| EPS | $-0.18 | $-0.51 | $-0.82 | $-0.92 | $-1.07 |
Company Overview
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
57%
Hold / Neutral
3
43%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
4 Bullish3 Neutral/Bearish
Price Targets
$25
Average Target
↑ 72.8% Upside
Now
$11
Low
$25
Average
$108
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 17th 2025 | Citigroup | Initiation | Buy | $17 |
| September 18th 2025 | Needham | Upgrade | Buy | $14 |
| July 17th 2025 | Morgan Stanley | Upgrade | Overweight | $108 |
| December 13th 2024 | Morgan Stanley | Downgrade | Equal Weight | $12← $17 |
| September 6th 2024 | Jefferies | Initiation | Buy | $18 |
| May 30th 2024 | Wells Fargo | Initiation | Overweight | $18 |
| May 14th 2024 | Guggenheim | Upgrade | Buy | $13 |
| December 19th 2023 | Morgan Stanley | Upgrade | Overweight | $20← $15 |
| September 9th 2022 | Morgan Stanley | Initiation | Equal Weight | $14 |
| April 13th 2022 | Goldman | Resumed | Neutral | $11 |
Earnings History & Surprises
FOLDBeat Rate
50%
Last 18 quarters
Avg Surprise
+6.5%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$0.17
Q4 2025
EPS Surprise History
Q1 24
-83.3%
$-0.11vs$-0.06
Q2 24
+66.7%
$-0.02vs$-0.06
Q3 24
+9.8%
$0.06vs$0.05
Q4 24
+25.0%
$0.10vs$0.08
Q1 25
+350.0%
$0.09vs$0.02
Q2 25
-62.5%
$0.03vs$0.08
Q3 25
-50.0%
$0.01vs$0.02
Q4 25
+41.7%
$0.17vs$0.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $0.14 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.12 | $0.17 | +41.7% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $0.02 | $0.01 | -50.0% | ✗ MISS |
Q2 2025 | May 1, 2025 | $0.08 | $0.03 | -62.5% | ✗ MISS |
Q1 2025 | Feb 19, 2025 | $0.02 | $0.09 | +350.0% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.08 | $0.10 | +25.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $0.05 | $0.06 | +9.8% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.06 | $-0.02 | +66.7% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.06 | $-0.11 | -83.3% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.12 | $-0.15 | -25.0% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.13 | $-0.18 | -38.5% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-0.13 | $-0.19 | -46.2% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-0.19 | $-0.12 | +36.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.24 | $-0.30 | -25.0% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.14 | $-0.29 | -107.1% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.18 | $-0.19 | -5.6% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.21 | $-0.19 | +9.5% | ✓ BEAT |
Latest News
BioMarin Pharmaceutical shares are trading higher after the company announced an agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of ~$4.8 billion.
📈 PositiveBenzinga•Dec 19, 2025, 08:25 PM•Also:
Needham Downgrades Amicus Therapeutics to Hold
📉 NegativeBenzinga•Dec 19, 2025, 04:17 PM
Cantor Fitzgerald Downgrades Amicus Therapeutics to Neutral, Lowers Price Target to $14.5
📉 NegativeBenzinga•Dec 19, 2025, 03:28 PM
Amicus Therapeutics shares are trading higher after the company announced it will be acquired by BioMarin.
📈 PositiveBenzinga•Dec 19, 2025, 01:56 PM•Also:
BioMarin to acquire rare disease drug developer Amicus for $4.8B
📈 PositiveSeeking Alpha•Dec 19, 2025, 12:59 PM•Also:
Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 19, 2025, 12:55 PM
Amicus Resolves Patent Litigation Over Aurobindo, Lupin Generic Filings For Galafold 123 mg Capsules
📈 PositiveBenzinga•Dec 19, 2025, 12:51 PM
BioMarin To Acquire Amicus For $14.50/Shr In All-Cash Transaction For Total Equity Value Of ~$4.8B
➖ NeutralBenzinga•Dec 19, 2025, 12:48 PM•Also:
Trading Halt: Halted at 7:40:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 19, 2025, 12:40 PM
Citigroup Initiates Coverage On Amicus Therapeutics with Buy Rating, Announces Price Target of $17
📈 PositiveBenzinga•Dec 17, 2025, 03:22 PM•Also:
Northern Dynasty Reports Mining Associations And US Chamber File Amicus Briefs Against Obama Biden Era Veto
📈 PositiveBenzinga•Dec 1, 2025, 11:47 AM•Also:
JP Morgan Maintains Overweight on Amicus Therapeutics, Raises Price Target to $19
📈 PositiveBenzinga•Nov 6, 2025, 09:18 PM
Goldman Sachs Maintains Neutral on Amicus Therapeutics, Raises Price Target to $11
➖ NeutralBenzinga•Nov 5, 2025, 04:50 PM
Amicus Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 4, 2025, 04:31 PM
Amicus 2025 Outlook Reiterates Financial Guidance With Revenue Growth Target Of 15% To 22% Reflecting Continued Business Expansion
📈 PositiveBenzinga•Nov 4, 2025, 12:04 PM
Amicus Therapeutics Q3 Adj. EPS $0.17 Beats $0.04 Estimate, Sales $169.061M Beat $165.706M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 12:02 PM
Needham Upgrades Amicus Therapeutics to Buy, Announces $14 Price Target
📈 PositiveBenzinga•Sep 18, 2025, 10:00 AM
Amicus Therapeutics Reports 4-Year Muscle Function And Biomarker Data From PROPEL Study Of Cipaglucosidase Alfa + Miglustat In Late-Onset Pompe Disease
➖ NeutralBenzinga•Sep 8, 2025, 01:05 PM
Frequently Asked Questions about FOLD
What is FOLD's current stock price?
Amicus Therapeutics, Inc. (FOLD) is currently trading at $14.18 per share. The stock has moved +30.21% today.
What is the analyst price target for FOLD?
The average analyst price target for FOLD is $14.50, based on 1 analyst.
What sector is Amicus Therapeutics, Inc. in?
Amicus Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is FOLD's market cap?
Amicus Therapeutics, Inc. has a market capitalization of $4.38 billion, making it a mid-cap company.
Does FOLD pay dividends?
No, Amicus Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
ARQT
Arcutis Biotherapeutics, Inc.
$28.01
Mkt Cap: $3.4B
CDTX
Cidara Therapeutics, Inc.
$220.80
Mkt Cap: $5.6B
CPRX
Catalyst Pharmaceuticals, Inc.
$23.74
Mkt Cap: $2.9B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
KNSA
Kiniksa Pharmaceuticals, Ltd.
$43.19
Mkt Cap: $3.2B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
MLYS
Mineralys Therapeutics, Inc.
$36.83
Mkt Cap: $2.4B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
TARS
Tarsus Pharmaceuticals, Inc.
$81.40
Mkt Cap: $3.5B
Explore stocks similar to FOLD for comparison